Company profile: Grid Therapeutics
1.1 - Company Overview
Company description
- Provider of AI-driven platforms and therapeutics for cancer, including GT103, a human-derived antibody targeting a tumor-specific epitope for lung and other cancers. Offerings include high-throughput antibody discovery without prior protein knowledge, an AI-driven data warehouse, computational biology tools, a tumor vaccine design program, and a Phase 1b NSCLC study of GT103.
Products and services
- AI-Driven Platform Innovation: Develops a high-throughput system that discovers human-derived antibodies for oncology by applying AI to identify novel targets without prior protein knowledge
- GT103: Constructs a human-derived, tumor-specific antibody that targets a unique epitope to treat lung cancer and potentially other malignancies, evaluated as monotherapy in advanced-stage NSCLC
- Data Warehouse: Engineers an AI-driven data warehouse designed for the discovery of novel cancer targets, therapeutic antibodies, and biomarkers
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Grid Therapeutics
ImmunOs Therapeutics
HQ: Switzerland
Website
- Description: Provider of next-generation human immunomodulatory therapeutics. The clinical-stage company develops IOS-1002, an immunotherapy targeting multiple immune-suppressive receptors for solid tumors and hematologic malignancies; an HLA-based platform for biologics against cancer and autoimmune diseases; and antibodies blocking specific HLA molecules for autoimmune conditions.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ImmunOs Therapeutics company profile →
Alentis Therapeutics
HQ: Switzerland
Website
- Description: Provider of CLDN1-targeted therapeutics for CLDN1+ cancers and fibrosis. This clinical-stage Swiss-French biotech develops anti-CLDN1 antibodies and ADCs, including ALE.C04 (mAb for CLDN1+ tumors that opens the collagen barrier), Lixudebart (mAb to reverse liver, kidney, and lung fibrosis), and preclinical ADCs ALE.P02 (delivers a tubulin inhibitor) and ALE.P03 (delivers a topoisomerase I inhibitor) into tumor cells.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Alentis Therapeutics company profile →
Vitaeris
HQ: Canada
Website
- Description: Provider of clinical-stage biopharmaceutical development by a Canadian company focused on the anti-interleukin-6 monoclonal antibody Clazakizumab, with global exclusive rights licensed from Alder Biopharmaceuticals, pursuing applications in chronic inflammatory diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Vitaeris company profile →
Immunovant
HQ: United States
Website
- Description: Provider of clinical-stage biopharmaceutical offerings focused on enabling normal lives for patients with autoimmune diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Immunovant company profile →
T-knife Therapeutics
HQ: Germany
Website
- Description: Provider of T cell receptor-based therapies for cancer, using a humanized TCR mice platform carrying human TCRαβ gene loci to recombine a broad repertoire of human TCRs, enabling efficient generation and virtual selection of receptors targeting human tumor antigens.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full T-knife Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Grid Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Grid Therapeutics
2.2 - Growth funds investing in similar companies to Grid Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Grid Therapeutics
4.2 - Public trading comparable groups for Grid Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →